Oregon Psilocybin Services Act (Measure 109)

Measure 109 Implementation

Ballot Measure 109 (2020) directs the Oregon Health Authority (OHA) — after a two-year development period from January 1, 2021 to December 31, 2022 — to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products and the provision of psilocybin services. During the two year development period OHA will work with the Oregon Psilocybin Advisory Board to establish rules and regulations implementing Measure 109 and the use of psilocybin products and services.

OHA will not be issuing licenses or accepting applications related to the manufacture, sale and purchase of psilocybin products and the provision of psilocybin services until January 2, 2023.

Read Measure 109 - The Oregon Psilocybin Services Act

Oregon Psilocybin Advisory Board

Established by Ballot Measure 109 (2020), the Oregon Psilocybin Advisory Board makes recommendations to OHA on available scientific studies and research on the safety and efficacy of psilocybin in treating mental health conditions, and makes recommendations on the requirements, specifications and guidelines for providing psilocybin services in Oregon. The Board will also develop a long-term strategic plan for ensuring that psilocybin services will become and remain a safe, accessible and affordable therapeutic option for all persons 21 years of age and older in this state for whom psilocybin may be appropriate; and monitor and study federal laws, regulations and policies regarding psilocybin.

Advisory Board Meetings

First meeting date, time and location TBD.

Scientific Literature Review

Safety and efficacy of psilocybin in treating mental health conditions

By June 30, 2021, the board will submit its findings and recommendations to the Oregon Health Authority on the available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

By July 31, 2021, and from time to time after such date, the Oregon Health Authority shall publish and distribute to the public available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end of-life psychological distress.